Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX)

· seekingalpha.com

Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX stock is downgraded to hold.

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI